First neurotrophic keratitis patient treated with Oxervate

The first U.S. patient has been treated with Oxervate eye drops for neurotrophic keratitis, Dompé announced in a press release.
Oxervate (cenegermin-bkbj), a recombinant human nerve growth factor that was approved by the FDA in August 2018, has the potential to resolve neurotrophic keratitis in one 8-week treatment cycle.
“I am excited to be among the first physicians to treat neurotrophic keratitis patients with this new therapy,” Giacomina Massaro-Giordano, MD, of the Scheie Eye Institute at the University of Pennsylvania and an investigator in the Oxervate clinical trials,

Full Story →